A detailed history of Level Four Advisory Services, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Level Four Advisory Services, LLC holds 24,722 shares of BMY stock, worth $1.44 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
24,722
Previous 22,322 10.75%
Holding current value
$1.44 Million
Previous $927,000 37.97%
% of portfolio
0.06%
Previous 0.04%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $95,183 - $124,200
2,400 Added 10.75%
24,722 $1.28 Million
Q2 2024

Aug 09, 2024

SELL
$40.25 - $52.99 $163,817 - $215,669
-4,070 Reduced 15.42%
22,322 $927,000
Q4 2023

Feb 08, 2024

SELL
$48.48 - $57.85 $170,988 - $204,036
-3,527 Reduced 11.79%
26,392 $1.35 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $201,051 - $224,807
-3,473 Reduced 10.4%
29,919 $1.74 Million
Q2 2023

Jul 10, 2023

SELL
$63.71 - $70.74 $235,344 - $261,313
-3,694 Reduced 9.96%
33,392 $2.14 Million
Q1 2023

Jun 05, 2023

BUY
$65.71 - $74.53 $155,207 - $176,039
2,362 Added 6.8%
37,086 $2.57 Million
Q4 2022

Feb 13, 2023

BUY
$68.48 - $81.09 $712,808 - $844,065
10,409 Added 42.81%
34,724 $2.5 Million
Q3 2022

Nov 07, 2022

SELL
$0.13 - $76.84 $159 - $94,359
-1,228 Reduced 4.81%
24,315 $1.73 Million
Q2 2022

Aug 08, 2022

SELL
$72.62 - $79.98 $107,187 - $118,050
-1,476 Reduced 5.46%
25,543 $1.97 Million
Q1 2022

May 10, 2022

BUY
$61.48 - $73.72 $55,147 - $66,126
897 Added 3.43%
27,019 $1.97 Million
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $222,242 - $259,082
4,144 Added 18.86%
26,122 $1.63 Million
Q3 2021

Oct 12, 2021

SELL
$59.17 - $69.31 $822,463 - $963,409
-13,900 Reduced 38.74%
21,978 $1.3 Million
Q2 2021

Aug 09, 2021

SELL
$61.91 - $67.42 $64,448 - $70,184
-1,041 Reduced 2.82%
35,878 $2.4 Million
Q1 2021

May 10, 2021

BUY
$59.34 - $66.74 $21,006 - $23,625
354 Added 0.97%
36,919 $2.33 Million
Q4 2020

Feb 10, 2021

BUY
$57.74 - $65.43 $72,463 - $82,114
1,255 Added 3.55%
36,565 $2.27 Million
Q3 2020

Nov 02, 2020

BUY
$57.43 - $63.64 $66,848 - $74,076
1,164 Added 3.41%
35,310 $2.13 Million
Q2 2020

Aug 17, 2020

BUY
$54.82 - $64.09 $1.87 Million - $2.19 Million
34,146 New
34,146 $2.02 Million
Q2 2020

Jul 27, 2020

SELL
$54.82 - $64.09 $1.71 Million - $2 Million
-31,222 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$46.4 - $67.43 $41,760 - $60,687
900 Added 2.97%
31,222 $1.74 Million
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $465,920 - $607,750
9,468 Added 45.4%
30,322 $1.95 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $41,657 - $49,391
974 Added 4.9%
20,854 $1.06 Million
Q2 2019

Aug 14, 2019

BUY
$44.62 - $49.34 $246,168 - $272,208
5,517 Added 38.41%
19,880 $901,000
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $126,832 - $151,231
2,811 Added 24.33%
14,363 $686,000
Q4 2018

Feb 08, 2019

BUY
$48.76 - $63.23 $46,809 - $60,700
960 Added 9.06%
11,552 $600,000
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $5,850 - $6,598
106 Added 1.01%
10,592 $658,000
Q2 2018

Aug 14, 2018

SELL
$50.53 - $62.98 $266,646 - $332,345
-5,277 Reduced 33.48%
10,486 $580,000
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $62,916 - $72,429
-1,050 Reduced 6.25%
15,763 $997,000
Q4 2017

Feb 13, 2018

BUY
$59.94 - $65.35 $5,754 - $6,273
96 Added 0.57%
16,813 $1.03 Million
Q3 2017

Apr 03, 2018

SELL
$55.23 - $63.74 $53,738 - $62,019
-973 Reduced 5.5%
16,717 $1.07 Million
Q3 2017

Nov 15, 2017

BUY
$55.23 - $63.74 $276,978 - $319,656
5,015 Added 39.57%
17,690 $1.14 Million
Q2 2017

Sep 20, 2017

SELL
N/A
-272 Reduced 2.1%
12,675 $673,000
Q1 2017

Sep 20, 2017

BUY
N/A
12,947
12,947 $688,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Level Four Advisory Services, LLC Portfolio

Follow Level Four Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Level Four Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Level Four Advisory Services, LLC with notifications on news.